| Literature DB >> 35400000 |
Edelyn S Azurin1,2, Norio Yamamoto1, Katsuhiro Hayashi1, Akihiko Takeuchi1, Shinji Miwa1, Kentaro Igarashi1, Takashi Higuchi1, Hirotaka Yonezawa1, Sei Morinaga1, Yohei Asano1, Shiro Saito1, Hiroyuki Tsuchiya1.
Abstract
Background/Aim: This study aimed to present a rare case of fibrous dysplasia (FD) in a healthy young adult man with a concomitant osteoporotic vertebral compression fracture. FD is a benign lesion of the bone characterized by replacement of the medullary component with fibro-osseous tissue that contains abnormally arranged trabeculae of immature woven bone. Recently it has been reported that several bone tumors including FD express the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL). Therefore, we hypothesized that FD contributed to osteoporosis, linked by the RANK-RANKL pathway of osteoclastogenesis. Case Report: We report the case of a healthy man with monostotic femoral fibrous dysplasia (FD) with concomitant 7 th thoracic vertebra compression fracture due to osteoporosis [young adult mean (YAM) was 79% in bone mineral density (BMD)]. After curettage of the FD, artificial bone grafting in the cavity, and administration of alendronate sodium, BMD improved considerably within 9 months. FD is a benign bone condition in which abnormal fibrous tissue replaces normal bone. The axis of the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL) has been implicated in osteoporosis pathogenesis. RANKL immunohistochemical staining was performed, and strong staining of stromal cells was observed compared to other FD cases that showed weak to moderate staining.Entities:
Keywords: Fibrous dysplasia; alendronate sodium; bone mineral density; osteoporosis; receptor activator of nuclear factor-kappa B ligand (RANKL); receptor activator of nuclear factorkappa B (RANK); vertebral fracture
Year: 2022 PMID: 35400000 PMCID: PMC8962839 DOI: 10.21873/cdp.10082
Source DB: PubMed Journal: Cancer Diagn Progn ISSN: 2732-7787